GeneDx Holdings Management
Management criteria checks 0/4
GeneDx Holdings' CEO is Katherine Stueland, appointed in May 2022, has a tenure of 1.92 years. total yearly compensation is $12.03M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $745.01K. The average tenure of the management team and the board of directors is 1 years and 2.8 years respectively.
Key information
Katherine Stueland
Chief executive officer
US$12.0m
Total compensation
| CEO salary percentage | 3.8% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Sema4 Holdings, Big Data For Precision Medicine Solutions
Jul 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$176m |
| Sep 30 2023 | n/a | n/a | -US$459m |
| Jun 30 2023 | n/a | n/a | -US$494m |
| Mar 31 2023 | n/a | n/a | -US$533m |
| Dec 31 2022 | US$12m | US$454k | -US$549m |
Compensation vs Market: Katherine's total compensation ($USD12.03M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Insufficient data to compare Katherine's compensation with company performance.
CEO
Katherine Stueland (47 yo)
1.9yrs
Tenure
US$12,033,388
Compensation
Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.9yrs | US$12.03m | 0.26% $ 745.0k | |
| Chief Financial Officer | 1.7yrs | US$3.76m | 0.11% $ 323.1k | |
| Senior VP & Head of Operations | less than a year | no data | no data | |
| Chief Product & Technology Officer | less than a year | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Chief Medical Officer | 1.9yrs | no data | no data | |
| Chief Growth Officer | less than a year | no data | no data | |
| Chief of Staff | no data | no data | no data |
1.0yrs
Average Tenure
Experienced Management: WGS's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.9yrs | US$12.03m | 0.26% $ 745.0k | |
| Independent Director | 6.4yrs | US$272.85k | 0.75% $ 2.2m | |
| Director | 2yrs | US$460.43k | 0.080% $ 233.7k | |
| Independent Director | 2.3yrs | US$272.85k | 0.0053% $ 15.4k | |
| Independent Director | 3.8yrs | US$262.22k | 0% $ 0 | |
| Chairman of the Board | 2.8yrs | US$3.19m | 0.72% $ 2.1m | |
| Independent Director | 3.6yrs | US$262.85k | 0.0097% $ 28.2k |
2.8yrs
Average Tenure
49.5yo
Average Age
Experienced Board: WGS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.